Actavis sees 2Q loss but Warner deal has reached final stages
This article was originally published in Scrip
Executive Summary
Generic drug developer Actavis has posted a second quarter loss of $4.27 per share, despite reporting a 47% increase in revenues, because of "restructuring costs." The Parsippany, New Jersey-based firm, previously known as Watson Pharmaceuticals, said the costs arose from the 2009 acquisition of UK drug maker Arrow. The combined assets were subsequently restructured from one global reporting unit into four new reporting units.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.